SIG
ABBV icon

Sargent Investment Group’s AbbVie ABBV Stock Holding History

Sargent Investment Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.86M Buy
45,348
+1,263
+3% +$280K 1.3% 20
2025
Q4 		$10.1M Buy
44,085
+476
+1% +$108K 1.26% 20
2025
Q3 		$10.1M Buy
43,609
+1,960
+5% +$399K 1.44% 19
2025
Q2 		$8.18M Buy
41,649
+3,028
+8% +$563K 1.11% 23
2025
Q1 		$8.09M Buy
38,621
+2,335
+6% +$454K 1.29% 21
2024
Q4 		$6.41M Sell
36,286
-10,876
-23% -$2M 1.05% 24
2024
Q3 		$9.31M Buy
47,162
+1,470
+3% +$274K 1.67% 17
2024
Q2 		$7.84M Buy
45,692
+41,296
+939% +$6.84M 1.6% 17
2024
Q1 		$801K Sell
4,396
-4,173
-49% -$719K 0.18% 94
2023
Q4 		$1.33M Buy
8,569
+625
+8% +$91.1K 0.29% 69
2023
Q3 		$1.18M Sell
7,944
-508
-6% -$74.6K 0.29% 71
2023
Q2 		$1.14M Sell
8,452
-460
-5% -$67.5K 0.28% 72
2023
Q1 		$1.43M Buy
8,912
+489
+6% +$74.8K 0.38% 60
2022
Q4 		$1.36M Sell
8,423
-25
-0.3% -$3.83K 0.42% 59
2022
Q3 		$1.19M Buy
8,448
+660
+8% +$94.7K 0.37% 63
2022
Q2 		$1.19M Buy
7,788
+390
+5% +$59.6K 0.37% 60
2022
Q1 		$1.2M Sell
7,398
-50
-0.7% -$7.26K 0.3% 60
2021
Q4 		$1.01M Buy
7,448
+200
+3% +$23.6K 0.23% 75
2021
Q3 		$782K Buy
7,248
+171
+2% +$19.5K 0.19% 88
2021
Q2 		$797K Buy
7,077
+875
+14% +$98.5K 0.19% 85
2021
Q1 		$671K Buy
6,202
+2,700
+77% +$289K 0.18% 98
2020
Q4 		$375K Buy
3,502
+900
+35% +$86.5K 0.12% 128
2020
Q3 		$228K Buy
2,602
+237
+10% +$22.3K 0.08% 146
2020
Q2 		$234K Buy
+2,365
New +$208K 0.09% 131
2019
Q2 		– Sell
-2,675
Closed -$216K – 144
2019
Q1 		$216K Sell
2,675
-510
-16% -$41.7K 0.1% 126
2018
Q4 		$294K Buy
+3,185
New +$280K 0.18% 94

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sargent Investment Group's ABBV Position: Q1 2026 in Review

Sargent Investment Group increased its AbbVie (ABBV) stake by 2.9% in Q1 2026, buying an estimated $280K and bringing the position to 45,348 shares worth $9.86M. The position accounts for 1.3% of the portfolio, ranked #20.

Sargent Investment Group first reported a position in ABBV in Q4 2018 and has held it in 26 quarters since. The position peaked at $10.1M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Sargent Investment Group held 45,348 shares of AbbVie worth $9.86M as of Q1 2026.
  • Sargent Investment Group bought 1,263 AbbVie shares in Q1 2026, an estimated $280K.
  • AbbVie made up 1.3% of Sargent Investment Group's portfolio in Q1 2026, its #20 holding.
  • Sargent Investment Group first reported a position in AbbVie in Q4 2018 and has held it in 26 quarters since.
  • Sargent Investment Group's AbbVie position peaked at $10.1M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sargent Investment Group's 13F filing for Q1 2026, filed 11 May 2026.